Quantcast

Hovione Announces Filing of Patent for New Powder Inhaler

June 14, 2011

LISBON, Portugal, June 14, 2011 /PRNewswire/ –

Hovione announced today the international filing of its latest patent
covering a new, highly efficient dry powder inhaler (DPI), XCaps.

XCaps fills a void in the pulmonary inhalation market, as a device which
combines high efficiency in powder dispersion with ease of use. Lung
fractions in excess of 70% have been achieved, from a device which only
requires two steps to inhalation and which only has two components plus a
dust cover. This makes XCaps highly suited for inhalation applications where
minimal training of patients is desirable and has the versatility to treat
almost all pulmonary diseases, including asthma, COPD and infection.

XCaps follows on the heels of another successful Hovione DPI,
TwinCaps(R), which was developed specifically for an influenza application
and is licensed to Daiichi Sankyo and Biota for this application. Daiichi
Sankyo launched Inavir(R) in the Japanese market in October 2010 and monthly
sales in Japan of this TwinCaps(R)-delivered neuraminidase inhibitor since
then have surpassed those of Roche’s Tamiflu(R) (1, 2).

Hovione is offering XCaps in optional conjunction with its drug product
development program, allowing potential licensees to take their candidate
drugs from the API stage all the way to the unit dose, under one roof. “We
give our customers an edge in speed of development because we are perhaps
the only independent company developing DPIs with expertise in every aspect
of the inhaled drug development process”, said Peter Villax, Vice-President
and co-inventor of the device.

Phil Nelson, Business Development Manager, said “Hovione has
wide-ranging expertise in the field of inhalation products. With our core
API process development and manufacturing expertise, we can manufacture
pharmaceutical ingredients where the final crystallization step produces
pulmonary delivery-friendly particles. Alternatively, we can use other
particle formulation technologies, such as spray-drying and we are currently
pioneering new particle technologies for stable, large dose delivery.”
Hovione is currently executing inhaled drug development projects for 5
pharmaceutical companies, involving API process development, particle
engineering, formulation and clinical supplies.

About Hovione. Hovione is an international company with over 50 years’
experience in Active Pharmaceutical Ingredient development and compliant
manufacture. With four FDA inspected sites in the U.S., China, Ireland, and
Portugal, the company focuses on the most demanding customers, in the most
regulated markets. The company also offers integrated API, particle design
and formulation development and manufacturing. In the inhalation area,
Hovione is the only independent company offering such a broad range of
services.

More about XCaps at http://www.hovione.com/inhale

Sources:

        1)

http://www.biota.com.au/uploaded/154/1021733_76openbriefing-ceoonoutlo.p

          df
        2) FY2010 Consolidated Financial Overview, Chugai Pharmaceutical
          Co. Ltd., February 2, 2011

        Contacts at Hovione:
        Phil Nelson, PhD                  Isabel Pina
        Business Development Manager      Corporate Communications
        pnelson@hovione.com               ipina@hovione.com
        +351-219-847-619                  +351-21-982-9362

http://www.hovione.com


Source: newswire



comments powered by Disqus